ClinicalTrials.gg
RecruitingNCT07405229RIME-IVFUpdated Sep 1, 2026

MEdical Treatment in Idiopathic Ventricular Fibrillation Patients

A Phase 4 interventional study of Beta-blocker treatment group in Idiopathic Ventricular Fibrillation and Cardiac Arrest, Out-Of-Hospital, sponsored by Bo Gregers Winkel. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Bo Gregers Winkel · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 years 8 months after the study started (first participant enrolled May 2018, registered Jan 2026).
  • Started May 2018; still recruiting 8 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark — 7 open to participants now, 8 under way, 2 of them phase 3. Out-of-Hospital Cardiac Arrest · Denmark.

Planned enrollment
19th of 26
218 · median 376
Started
2018
with 7 others
Phase 4
2 of 38
2 open now
Registered
38th of 38
by date
Lead sponsor
1 of 38
Bo Gregers Winkel

Among the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, this one is the 19th largest by planned enrollment of the 26 interventional ones that give a count, is one of 8 that started in 2018, is one of 2 in phase 4, and was the 38th registered.

Out-of-Hospital Cardiac Arrest

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

Browse Out-of-Hospital Cardiac Arrest studies →

Open to participants now

7 of the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, or all of them as a file.
02

Study summary

A person who has experienced a cardiac arrest with no apparent cause is at risk of having recurrent cardiac arrest. Hence an implantable cardioverter-defibrillator (ICD) is recommended on empirical grounds. Today, there is no uniform way of approaching prevention of recurrence in idiopathic ventricular fibrillation (IVF) patients, beside ICD implantation. Better reatment and risk stratification tools are needed Medical treatment in these patients has never been assessed systematically, but at least some patients with no apparent diagnosis are on betablocker treatment. It is not known if low-doselow dose betablocker treatment is beneficial in these patients.

This study investigates the effect of betablocker treatment to reduce arrhythmic burden in IVF patients.

No predictors for appropriate ICD therapy have been identified in patients with IVF. It is also explored if toxicological and/or genetic profiles, together with in depth machine learning simulation data on repolarization patterns from IVF-ECGs compared to controls, can be used as risk stratification tools.

Lastly, QOL in IVF patients and the impact of beta blocker treatment will be investigated.

03

Conditions studied

  • Idiopathic Ventricular Fibrillation
  • Cardiac Arrest, Out-Of-Hospital

Keywords

  • Idiopathic Ventricular Fibrillation
  • IVF
  • cardiac arrest
  • beta-blocker
  • treatment
  • ventricular tachyarrhythmias
  • Risk markers
  • quality of life
  • QoL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Resuscitated OHCA patients admitted to one of the participating hospitals.

  1. Age ≥18 years
  2. Suspected cardiac cause of cardiac arrest

Exclusion criteria

Exclusion Criteria:

OHCA patients

  1. With Ischemic heart disease.
  2. Obvious non-cardiac cause of cardiac arrest
  3. Congenital heart disease
  4. Do not speak or understand Danish
  5. Foreigners -
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
218 participants (estimated)

Study arms

  • Active comparator
    Beta-blocker

    Drug: Beta-blocker treatment group

  • No intervention
    No medication

    Standard care

Interventions

  • DrugBeta-blocker treatment group

    The betablocker given to the patient will be prioritized: 1) A non-selective betablocker: Propranolol Retard 80 mg daily or Nadolol 40 mg daily OR 2) A selective betablocker: Atenolol 25 mg daily, Bisoprolol 2.5 mg daily or Metoprolol 50 mg.

06

What researchers measure

Primary outcomes

  1. First appropriate therapy by ICD or 3 years after discharge

    Primary outcome will be either first appropriate therapy by ICD (anti tachycardia pacing or DC conversion), or aborted shock or non-sustained ventricualr fibrillation detected by the ICD, where the treating physician opts for a change in medication, or no therapy from the ICD 3 years after randomization, whichever comes first.

    Time frame: 3 years

Secondary outcomes

  1. Quality of Life at 3 months

    Quality of life will be assessed by trained nurses. Focus will be on betablocker therapy and overall cognitive abilities after cardiac arrest. Patients will be assessed using the SF-36 (v1) quality of life tool. The patients will be assessed 3 months after discharge.

    Time frame: 3 months

  2. Quality of Life at 1 year

    Quality of life will be assessed by trained nurses. Focus will be on betablocker therapy and overall cognitive abilities after cardiac arrest. Patients will be assessed using the SF-36 (v1) quality of life tool. The patients will be assessed 3 1 year after discharge.

    Time frame: 1 year

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — GDPR

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2018 (actual). Primary completion is estimated for Dec 2032, 175 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 12, 2026
StartActual
May 1, 2018
Primary completionEst.
Dec 31, 2032
CompletionEst.
Dec 31, 2035
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07405229
Lead sponsor
Bo Gregers Winkel
Collaborators
Novo Nordisk Foundation, Danish Heart Foundation
Responsible party
Bo Gregers Winkel (Chief Physician, Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Feb 12, 2026
Start date
May 1, 2018
Primary completion
Dec 31, 2032 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Sep 1, 2026

Study contacts

Bo G Winkel, MD, PhD
Contact
bo.winkel@regionh.dk
+4535459759
Bo G Winkel, MD
principal investigator · The Heart Center, Rigshospitalet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion